Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of Carboplatin Clearance Predictors Using Iohexol
NCT03997370Phase 1Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Jan 2020
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of iohexol in malignant solid neoplasm, sponsored by NRG Oncology. Primary endpoints: Accuracy of achieving the targeted carboplatin area under the curve (AUC) at 4 weeks, Precision of achieving the targeted carboplatin AUC at 4 weeks and 3 more. Started Jan 2020; status: active, not recruiting.
02
Drugs
iohexol
03
Conditions
malignant solid neoplasm
Beyond the preview
Go deeper on NCT03997370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03997370.